773 A phase 1b/2, open-label, dose escalation and expansion study of an anti-CTLA-4 NEOBodyTMADG116 in combination with pembrolizumab (anti-PD-1 antibody) in patients with advanced/metastatic solid tumors: a preliminary update
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.